Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898351 | 0.77 | KDM4E (0.48) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL9538499 | 0.76 | HMGCR (0.61) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL15844297 | 0.71 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL786021 | 0.71 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL9351424 | 0.71 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| Carbamic Acid SCHEMBL28424909 | 0.70 | MCL1 (0.40) | KDM4EMCL1DPP4 | |
| SCHEMBL7845294 | 0.68 | ALDH1A1 (0.33) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL5789155 | 0.67 | — | — | |
| SCHEMBL17610936 | 0.67 | TSHR (0.36) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| Acetonitrile SCHEMBL1773605 | 0.67 | KDM4E (0.52) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2063914-B1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | ZENTIVA KS (CZ) | 2018-12-26 | — | — | EP | disclosed |
| US-9173949-B2 | Dendritic high-molecular-weight polymer drug carriers and their conjugates with drugs especially for treatment of solid tumours | USTAV MAKROMOLEKULARNI CHEMIE AV CR, V.V.I. (CZ) | 2015-11-03 | — | — | US | disclosed |
| EP-2512521-B1 | DENDRITIC HIGH-MOLECULAR-WEIGHT POLYMER DRUG CARRIERS AND THEIR CONJUGATES WITH DRUGS ESPECIALLY FOR TREATMENT OF SOLID TUMOURS | USTAV MAKROMOLEKULARNI CHEMIE (CZ) | 2014-02-26 | — | — | EP | disclosed |
| US-8603990-B2 | Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation | ZENTIVA K.S. (CS) | 2013-12-10 | — | — | US | disclosed |
| US-20120296048-A1 | Dendritic High-molecular-weight Polymer Drug Carriers and Their Conjugates with Drugs Especially for Treatment of Solid Tumours | MIKROBIOLOGICKY USTAV AV CR, V.V.I. (CZ) | 2012-11-22 | — | — | US | disclosed |
| EP-2512521-A2 | DENDRITIC HIGH-MOLECULAR-WEIGHT POLYMER DRUG CARRIERS AND THEIR CONJUGATES WITH DRUGS ESPECIALLY FOR TREATMENT OF SOLID TUMOURS | Ustav Makromolekularni Chemie AV CR, V.V.I. (CZ) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011072627-A2 | DENDRITIC HIGH-MOLECULAR-WEIGHT POLYMER DRUG CARRIERS AND THEIR CONJUGATES WITH DRUGS ESPECIALLY FOR TREATMENT OF SOLID TUMOURS | USTAV MAKROMOLEKULARNI CHEMIE AV CR, V.V.I. (CZ) | 2011-06-23 | — | — | WO | disclosed |
| US-20090306004-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | ZENTIVA K.S. (CZ) | 2009-12-10 | — | — | US | disclosed |
| EP-2063914-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | Zentiva, k.s. (CZ) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008034391-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | ZENTIVA, A.S. (CZ) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306004-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | DNPEP, HDGF, LNPEP | HMGCR 1036/4885CHRM1 4504/4885TBXA2R 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.